ECM Weekly (8 November 2020) - Ant, Sunac Svcs, Jinke Svcs, Antengene, Gland Pharma, Kalyan Jewel
Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
503 Views
Antengene: Gunning To Move Up in Line
This Insight provides an in-depth review of pre-revenue biotechnology Antegene that plans to list on the HKEX. We discuss the pipeline, market...
579 Views
Antengene (å¾·ēŖå»čÆ) Pre-IPO: Thoughts on Valuation
Antengene is a biotech company with a focus on in-licensed innovative oncology drugs. The company was founded by Dr Jay Mei, an ex-Celgene...
468 Views
Antengene IPO Initiation: Hunting for a Cure
Leveraging the management teamās expertise, Antegene focuses on the haematology and oncology therapeutic areas. Overall, we believe that Antegeneās...
403 Views
ECM Weekly (1 November 2020) - Ant Group, Sunac Services, New Oriental HK, Bio-Thera
This week, much of the focus is on Ant whereas HK had a disappoint start with the poor debut of KWG Living and Shimao Services. On the other hand,...
528 Views